Leaflet attached to the packaging: patient information
Warning! Keep the leaflet, information on the immediate packaging in a foreign language!
Concor Cor 2.5 (Concor Cor 2.5 mg), 2.5 mg, film-coated tablets
Bisoprolol fumarate
Concor Cor 2.5 and Concor Cor 2.5 mg are different trade names for the same medicine.
You should carefully read the contents of the leaflet before taking the medicine, as it contains important information for the patient.
- You should keep this leaflet, so that you can read it again if necessary.
- In case of any doubts, you should consult a doctor or pharmacist.
- This medicine has been prescribed to a specific person. Do not pass it on to others. The medicine may harm another person, even if the symptoms of their illness are the same.
- If the patient experiences any side effects, including any side effects not listed in this leaflet, they should tell their doctor or pharmacist. See section 4.
Table of contents of the leaflet
- 1. What is Concor Cor 2.5 and what is it used for
- 2. Important information before taking Concor Cor 2.5
- 3. How to take Concor Cor 2.5
- 4. Possible side effects
- 5. How to store Concor Cor 2.5
- 6. Contents of the packaging and other information
1. What is Concor Cor 2.5 and what is it used for
The active substance of Concor Cor 2.5 is bisoprolol fumarate. Bisoprolol belongs to a group of medicines called beta-adrenergic blockers. These medicines affect the body's response to certain nerve impulses, especially in the heart. As a result, bisoprolol slows down the heart rate and thus increases the efficiency of the heart in pumping blood throughout the body.
Heart failure occurs when the heart muscle is weak and cannot pump enough blood to meet the body's needs.
Concor Cor 2.5 is used to treat stable, chronic heart failure.
2. Important information before taking Concor Cor 2.5
When not to take Concor Cor 2.5
Do not take Concor Cor 2.5 in the following cases:
- if the patient is allergic to bisoprolol or any of the other ingredients of this medicine (listed in section 6),
- if the patient has severe asthma,
- if the patient has been diagnosed with severe circulatory disorders in the limbs (such as Raynaud's syndrome), which can cause tingling, pallor, or cyanosis of the fingers or toes,
- if the patient has an untreated pheochromocytoma, a rare tumor of the adrenal gland,
- if the patient has metabolic acidosis, a condition in which the blood pH is abnormal,
- if the patient has acute heart failure,
- if the patient's heart failure worsens and requires intravenous administration of medicines that increase heart contractility,
- if the patient has symptoms of slow heart rate,
- if the patient has symptoms of low blood pressure,
- if the patient has certain heart diseases that cause very slow or irregular heart rhythm (second- or third-degree atrioventricular block, sinoatrial block, sick sinus syndrome) without a pacemaker,
- if the patient has cardiogenic shock, an acute, life-threatening heart disorder that leads to low blood pressure and circulatory failure.
Warnings and precautions
If any of the following conditions occur, the patient should discuss them with their doctor before starting Concor Cor 2.5; the doctor may decide that special caution is required (e.g., additional medication or more frequent medical check-ups):
- diabetes,
- strict fasting,
- certain heart diseases (such as arrhythmias or severe chest pain at rest - Prinzmetal's angina),
- kidney or liver disorders,
- circulatory disorders in the limbs,
- mild asthma or chronic obstructive pulmonary disease,
- psoriasis (including a history of psoriasis),
- pheochromocytoma of the adrenal gland,
- thyroid dysfunction.
In addition, the patient should tell their doctor if they are planning:
- desensitization treatment (e.g., to avoid hay fever), as Concor Cor 2.5 may increase the risk of an allergic reaction or worsen such a reaction;
- undergoing surgery under general anesthesia, as Concor Cor 2.5 may alter the body's response to the anesthetics.
Children and adolescents
Concor Cor 2.5 is not recommended for children and adolescents.
Concor Cor 2.5 and other medicines
The patient should tell their doctor about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take.
Do not take the following medicines with Concor Cor 2.5 without special recommendation by the doctor:
- certain medicines used to treat arrhythmias (class I anti-arrhythmic medicines, such as quinidine, disopyramide, lidocaine, phenytoin, flecainide, propafenone);
2
- certain medicines used to treat high blood pressure, coronary artery disease, or arrhythmias (calcium antagonists, such as verapamil and diltiazem);
- certain medicines used to treat high blood pressure, such as clonidine, methyldopa, moxonidine, rilmenidine. However, do not stop taking these medicines without consulting a doctor.
Before taking the following medicines with Concor Cor 2.5, the patient should discuss them with their doctor, as the doctor may recommend more frequent medical check-ups:
- certain medicines used to treat high blood pressure or coronary artery disease (calcium antagonists of the dihydropyridine type, such as felodipine and amlodipine);
- certain medicines used to treat arrhythmias (class III anti-arrhythmic medicines, such as amiodarone);
- locally applied beta-adrenergic blockers (such as eye drops for glaucoma treatment);
- certain medicines used to treat, for example, Alzheimer's disease or glaucoma (parasympathomimetics);
- medicines used to treat acute heart disorders (adrenergic agonists, such as isoprenaline and dobutamine);
- insulin and oral anti-diabetic medicines;
- general anesthetics (e.g., during surgery);
- digitalis glycosides used to treat heart failure;
- non-steroidal anti-inflammatory medicines (NSAIDs) used to treat arthritis, relieve pain and inflammation (e.g., ibuprofen and diclofenac);
- adrenaline, a medicine used to treat severe, life-threatening allergic reactions and cardiac arrest;
- all medicines that may lower blood pressure, either as a desired or undesired effect, such as antihypertensive medicines, certain antidepressants (tricyclic antidepressants), certain antiepileptic medicines, or medicines used during general anesthesia (barbiturates), as well as certain medicines used in psychiatric disorders characterized by loss of contact with reality (phenothiazine derivatives);
- mefloquine, used to prevent and treat malaria;
- medicines used to treat depression, called monoamine oxidase inhibitors (except for MAO-B inhibitors);
- rifampicin, an antibiotic used to treat infections;
- ergotamine derivatives, medicines used to treat dementia and migraine headaches.
Pregnancy and breastfeeding
There is a risk that taking Concor Cor 2.5 during pregnancy may harm the baby.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a baby, they should consult their doctor or pharmacist before taking this medicine. The doctor will decide whether Concor Cor 2.5 can be taken during pregnancy.
It is not known whether bisoprolol passes into human milk, so breastfeeding is not recommended during treatment with Concor Cor 2.5.
Driving and using machines
The medicine may affect the ability to drive or use machines, depending on how it is tolerated. The patient should be particularly careful at the beginning of treatment, after increasing the dose, or when changing medicines, as well as when combining the medicine with alcohol.
3
3. How to take Concor Cor 2.5
This medicine should always be taken according to the doctor's recommendations. In case of doubts, the patient should consult their doctor or pharmacist.
Concor Cor is available in the following doses: 1.25 mg, 2.5 mg, 3.75 mg, 7.5 mg.
During treatment with Concor Cor 2.5, regular medical check-ups are necessary. This is especially important at the beginning of treatment, during dose increases, and when stopping treatment.
The tablet should be taken in the morning with food or independently of food, washed down with water. The tablets should not be chewed. Scored tablets can be divided into two equal doses.
Adults
The doctor will start treatment with bisoprolol at a low dose, which will be gradually increased - the doctor will decide how to increase the dose. The recommended initial dose is 1.25 mg once daily. The dose is increased at intervals of two weeks or more to 2.5 mg, 3.75 mg, 5 mg, 7.5 mg, and 10 mg once daily. This usually happens as follows:
- 1.25 mg of bisoprolol once daily for 2 weeks;
- 2.5 mg of bisoprolol once daily for 2 weeks;
- 3.75 mg of bisoprolol once daily for 2 weeks;
- 5 mg of bisoprolol once daily for 2 weeks;
- 7.5 mg of bisoprolol once daily for 2 weeks;
- 10 mg of bisoprolol once daily for maintenance (chronic) treatment.
The maximum recommended daily dose is 10 mg of bisoprolol.
Depending on how the medicine is tolerated, the doctor may recommend extending the time between dose increases. If the disease worsens or the medicine is not tolerated, it may be necessary to reduce the dose again or stop treatment. In some patients, a maintenance dose lower than 10 mg of bisoprolol may be sufficient.
The doctor will determine the appropriate course of action.
Impaired liver or kidney function
Special caution is necessary when increasing the dose of the medicine.
Elderly patients
Dose adjustment is not necessary.
Use in children and adolescents
Concor Cor 2.5 is not recommended for children and adolescents.
Duration of treatment
Treatment with Concor Cor 2.5 is usually long-term.
If treatment needs to be stopped, the doctor will usually recommend gradual reduction of the dose, otherwise the disease may worsen.
4
What to do if you take more Concor Cor 2.5 than you should
If you take more Concor Cor 2.5 than you should, you should immediately inform your doctor. The doctor will decide what actions to take.
Symptoms of overdose include: slow heart rate, difficulty breathing, significant drop in blood pressure, dizziness, or seizures (caused by low blood sugar levels).
What to do if you miss a dose of Concor Cor 2.5
Do not take a double dose to make up for a missed dose. The next morning, take the recommended dose.
What to do if you stop taking Concor Cor 2.5
Never stop taking Concor Cor 2.5 unless your doctor recommends it. Otherwise, the disease may worsen.
If you have any further doubts about taking this medicine, you should consult your doctor or pharmacist.
4. Possible side effects
Like all medicines, Concor Cor 2.5 can cause side effects, although not everybody gets them.
Very common(occurring in at least 1 in 10 patients):
- bradycardia (slow heart rate).
Common(occurring less often than 1 in 10 patients):
- worsening of existing heart failure,
- fatigue, asthenia (weakness), dizziness, headache,
- feeling of coldness or numbness in the hands or feet,
- low blood pressure,
- gastrointestinal disorders, such as nausea, vomiting, diarrhea, or constipation.
Uncommon(occurring less often than 1 in 100 patients):
- conduction disorders,
- sleep disorders,
- depression,
- bronchospasm (difficulty breathing) in patients with asthma or chronic obstructive pulmonary disease,
- muscle weakness or cramps.
Rare(occurring less often than 1 in 1000 patients):
- hearing disorders,
- allergic rhinitis,
- reduced tear secretion (should be considered if the patient wears contact lenses),
- hepatitis, which can cause yellowing of the skin or eyes,
- changes in the results of certain blood tests, related to liver function (increased ALT and AST activity) or triglyceride levels in the blood,
- allergic reactions, such as itching, flushing, rash. The patient should immediately contact their doctor if they experience more severe allergic reactions, which may include: swelling of the face, neck, tongue, mouth, or throat, or difficulty breathing,
- erectile dysfunction
- nightmares, hallucinations,
- fainting.
Very rare(occurring less often than 1 in 10,000 patients):
- conjunctivitis (irritation or redness of the eyes),
- hair loss,
- psoriasis (including a history of psoriasis) or psoriasis-like skin changes.
Reporting side effects
If you experience any side effects, including any side effects not listed in this leaflet, you should tell your doctor or pharmacist. Side effects can be reported directly to the Department of Drug Safety Monitoring of the State Agency of Medicines: Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl.
By reporting side effects, you can help provide more information on the safety of this medicine.
5. How to store Concor Cor 2.5
Keep the medicine out of the sight and reach of children.
Store in a temperature below 25°C.
Do not use this medicine after the expiry date stated on the blister pack and carton. The expiry date refers to the last day of the month.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
6. Contents of the packaging and other information
What Concor Cor 2.5 contains
- The active substance is bisoprolol fumarate. Each film-coated tablet contains 2.5 mg of bisoprolol fumarate.
- The other ingredients are: tablet core: colloidal anhydrous silica, magnesium stearate, crospovidone, microcrystalline cellulose, corn starch, calcium hydrogen phosphate; tablet coating: dimethicone, macrogol 400, titanium dioxide (E171), hypromellose.
6
What Concor Cor 2.5 looks like and contents of the pack
Concor Cor 2.5 is a white, film-coated tablet in the shape of a heart, with a score line on both sides of the tablet.
Each pack contains 30 or 60 film-coated tablets.
For more detailed information, the patient should contact the marketing authorization holder or the parallel importer.
Marketing authorization holder in Latvia, the country of export:
Merck Serono SIA
Duntes iela 23A
LV-1005 Riga
Latvia
Manufacturer:
Merck S.L.
Polígono Merck
08100 Mollet del Vallés
Barcelona
Spain
Merck Healthcare KGaA
Frankfurter Strasse 250
D-64293 Darmstadt
Germany
Parallel importer:
Medezin Sp. z o.o.
ul. Zbąszyńska 3
91-342 Łódź
Repackaged by:
Medezin Sp. z o.o.
ul. Zbąszyńska 3
91-342 Łódź
Marketing authorization number in Latvia, the country of export: 02-0168
Parallel import authorization number: 52/25
Date of leaflet approval: 07.02.2025
[Information about the trademark]
7